Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
All content for On The Pen With Dave Knapp is the property of Bleav, Dave Knapp Founder of On The Pen and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
This Week Dave breaks down:
The UK’s massive MHRA raid on a counterfeit GLP-1 operation and what it reveals about access gaps driving patients to unsafe sources.
Why Cigna’s promise to help patients sent their stock soaring and how PBMs like Express Scripts profit while pretending to reform.
Innovent’s Mazdutide showing stronger weight loss than semaglutide and what that means for global obesity drug innovation.
Terns Pharmaceuticals scaling back its metabolic programs after modest GLP-1 results, proof of how hard it is for small biotech to survive this race.
New Lancet data confirming semaglutide’s heart protection, even without diabetes.
Whistleblower allegations from Washington State involving Aequita Pharmacy and Mochi Health, claims that raise new questions about compounding safety.
Ro’s RAID-FN Food Noise scale, the first scientifically validated tool to measure something patients have felt for years but science couldn’t define.
On The Pen With Dave Knapp
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
